A prospective study of suramin-induced peripheral neuropathy
Identifieur interne : 004334 ( Istex/Checkpoint ); précédent : 004333; suivant : 004335A prospective study of suramin-induced peripheral neuropathy
Auteurs : V. Chaudhry [États-Unis] ; M. A. Eisenberger [États-Unis] ; V. J. Sinibaldi [États-Unis] ; K. Sheikh [États-Unis] ; J. W. Griffin [États-Unis] ; D. R. Cornblath [États-Unis]Source :
- Brain [ 0006-8950 ] ; 1996-12.
Abstract
Suramin is an investigational drug that has shown therapeutic activity in hormone-refractory metastatic prostate cancer in Phase I/II trials. Dose-limiting neurotoxicity remains the most serious complication of suramin treatment. We performed a prospective study to define the incidence, severity, characteristics, and dose relationships of suramin-induced peripheral neuropathy. Twenty-two patients who received suramin in a Phase-I trial underwent baseline and serial follow-up neurological evaluations consisting of history, examination, nerve conduction studies and quantitative sensory testing (QST). Suramin was administered intravenously in escalating dosages by using a 5-day schedule (repeated monthly), with the dose, determined by a population pharmacokinetic model, to accomplish 30-min post-infusion concentrations of 300 μg ml−1 (cohort I), 350 μg m−1 (cohort II) and 400 μg ml−1 (cohort III). Twelve patients developed a mild, axonal, length-dependent, sensory-motor polyneuropathy. Three other patients developed a subacutely progressive, functionally disabling, demyelinating neuropathy; sural nerve biopsy in two patients showed lymphocytic inflammation. These three patients improved after drug discontinuation and plasmapheresis. Although there was no apparent correlation between the cumulative dose and the severity of the neuropathy, no patient from cohort I, but 88% of patients from cohorts II and III, developed neuropathy. We conclude that when suramin is used at peak concentrations of ⋛350 μg ml−1 its administration is associated with two patterns of neuropathy, a distal axonal neuropathy and an inflammatory demyelinating neuropathy that is partially reversible. Neurological monitoring for development of neuropathy will improve the safety of suramin use in future clinical studies.
Url:
DOI: 10.1093/brain/119.6.2039
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:185480A9AF5D45D341E2A8AF7601DB02AE84E765Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A prospective study of suramin-induced peripheral neuropathy</title><author><name sortKey="Chaudhry, V" sort="Chaudhry, V" uniqKey="Chaudhry V" first="V." last="Chaudhry">V. Chaudhry</name></author><author><name sortKey="Eisenberger, M A" sort="Eisenberger, M A" uniqKey="Eisenberger M" first="M. A." last="Eisenberger">M. A. Eisenberger</name></author><author><name sortKey="Sinibaldi, V J" sort="Sinibaldi, V J" uniqKey="Sinibaldi V" first="V. J." last="Sinibaldi">V. J. Sinibaldi</name></author><author><name sortKey="Sheikh, K" sort="Sheikh, K" uniqKey="Sheikh K" first="K." last="Sheikh">K. Sheikh</name></author><author><name sortKey="Griffin, J W" sort="Griffin, J W" uniqKey="Griffin J" first="J. W." last="Griffin">J. W. Griffin</name></author><author><name sortKey="Cornblath, D R" sort="Cornblath, D R" uniqKey="Cornblath D" first="D. R." last="Cornblath">D. R. Cornblath</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:185480A9AF5D45D341E2A8AF7601DB02AE84E765</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1093/brain/119.6.2039</idno><idno type="url">https://api.istex.fr/document/185480A9AF5D45D341E2A8AF7601DB02AE84E765/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B28</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B28</idno><idno type="wicri:Area/Istex/Curation">000B28</idno><idno type="wicri:Area/Istex/Checkpoint">004334</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">004334</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">A prospective study of suramin-induced peripheral neuropathy</title><author><name sortKey="Chaudhry, V" sort="Chaudhry, V" uniqKey="Chaudhry V" first="V." last="Chaudhry">V. Chaudhry</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology, Johns Hopkins University School of Medicine Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Eisenberger, M A" sort="Eisenberger, M A" uniqKey="Eisenberger M" first="M. A." last="Eisenberger">M. A. Eisenberger</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Oncology, Johns Hopkins University School of Medicine Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Sinibaldi, V J" sort="Sinibaldi, V J" uniqKey="Sinibaldi V" first="V. J." last="Sinibaldi">V. J. Sinibaldi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Oncology, Johns Hopkins University School of Medicine Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Sheikh, K" sort="Sheikh, K" uniqKey="Sheikh K" first="K." last="Sheikh">K. Sheikh</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology, Johns Hopkins University School of Medicine Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Griffin, J W" sort="Griffin, J W" uniqKey="Griffin J" first="J. W." last="Griffin">J. W. Griffin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology, Johns Hopkins University School of Medicine Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neuroscience, Johns Hopkins University School of Medicine Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Cornblath, D R" sort="Cornblath, D R" uniqKey="Cornblath D" first="D. R." last="Cornblath">D. R. Cornblath</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology, Johns Hopkins University School of Medicine Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain</title><idno type="ISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1996-12">1996-12</date><biblScope unit="volume">119</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="2039">2039</biblScope><biblScope unit="page" to="2052">2052</biblScope></imprint><idno type="ISSN">0006-8950</idno></series><idno type="istex">185480A9AF5D45D341E2A8AF7601DB02AE84E765</idno><idno type="DOI">10.1093/brain/119.6.2039</idno><idno type="ArticleID">119.6.2039</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Suramin is an investigational drug that has shown therapeutic activity in hormone-refractory metastatic prostate cancer in Phase I/II trials. Dose-limiting neurotoxicity remains the most serious complication of suramin treatment. We performed a prospective study to define the incidence, severity, characteristics, and dose relationships of suramin-induced peripheral neuropathy. Twenty-two patients who received suramin in a Phase-I trial underwent baseline and serial follow-up neurological evaluations consisting of history, examination, nerve conduction studies and quantitative sensory testing (QST). Suramin was administered intravenously in escalating dosages by using a 5-day schedule (repeated monthly), with the dose, determined by a population pharmacokinetic model, to accomplish 30-min post-infusion concentrations of 300 μg ml−1 (cohort I), 350 μg m−1 (cohort II) and 400 μg ml−1 (cohort III). Twelve patients developed a mild, axonal, length-dependent, sensory-motor polyneuropathy. Three other patients developed a subacutely progressive, functionally disabling, demyelinating neuropathy; sural nerve biopsy in two patients showed lymphocytic inflammation. These three patients improved after drug discontinuation and plasmapheresis. Although there was no apparent correlation between the cumulative dose and the severity of the neuropathy, no patient from cohort I, but 88% of patients from cohorts II and III, developed neuropathy. We conclude that when suramin is used at peak concentrations of ⋛350 μg ml−1 its administration is associated with two patterns of neuropathy, a distal axonal neuropathy and an inflammatory demyelinating neuropathy that is partially reversible. Neurological monitoring for development of neuropathy will improve the safety of suramin use in future clinical studies.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Chaudhry, V" sort="Chaudhry, V" uniqKey="Chaudhry V" first="V." last="Chaudhry">V. Chaudhry</name></region><name sortKey="Cornblath, D R" sort="Cornblath, D R" uniqKey="Cornblath D" first="D. R." last="Cornblath">D. R. Cornblath</name><name sortKey="Eisenberger, M A" sort="Eisenberger, M A" uniqKey="Eisenberger M" first="M. A." last="Eisenberger">M. A. Eisenberger</name><name sortKey="Griffin, J W" sort="Griffin, J W" uniqKey="Griffin J" first="J. W." last="Griffin">J. W. Griffin</name><name sortKey="Griffin, J W" sort="Griffin, J W" uniqKey="Griffin J" first="J. W." last="Griffin">J. W. Griffin</name><name sortKey="Sheikh, K" sort="Sheikh, K" uniqKey="Sheikh K" first="K." last="Sheikh">K. Sheikh</name><name sortKey="Sinibaldi, V J" sort="Sinibaldi, V J" uniqKey="Sinibaldi V" first="V. J." last="Sinibaldi">V. J. Sinibaldi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004334 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 004334 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:185480A9AF5D45D341E2A8AF7601DB02AE84E765
|texte= A prospective study of suramin-induced peripheral neuropathy
}}
| This area was generated with Dilib version V0.6.31. |  |